VDAC1 and urinary bladder carcinoma: Here, we focused on bladder cancer, testing the effects of VDAC1 silencing using siRNA, recognizing both mouse and human VDAC1 on BC cell lines and two BC mouse models, and demonstrated that reprogramming cancer cell metabolism by VDAC1 silencing resulted in a reversal of oncogenic properties (Figure 10), as found in other cancer types [14,15,16,17].